Key Documents

View All Documentation

SML1768

Ximelagatran

Name: Ximelagatran
Brand: SIGMA

≥98% (HPLC), Thrombin inhibitor, powder

Synonym(s):

H 376/95, N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-glycine ethyl ester

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₃₅N₅O₅

CAS Number:

192939-46-1

Molecular Weight:

473.57

UNSPSC Code:

51111800

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Ximelagatran, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

N/C(C1=CC=C(CNC([C@@H]2CCN2C([C@@H](C3CCCCC3)NCC(OCC)=O)=O)=O)C=C1)=N/O

InChI

1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1

InChI key

ZXIBCJHYVWYIKI-PZJWPPBQSA-N

Description

Biochem/physiol Actions

It inhibits both clot-bound and free thrombin. It is quickly absorbed by the small intestine and converted to its active dipeptide drug form, Melagatran. Melagatran associates with the arginine side pocket in thrombin and inactivates it. Ximelagatran has a half-life of 4-5 hours. It is administered orally twice a day.

Orally active direct thrombin inhibitor; prodrug of melagatran.

Ximelagatran is orally active, selective and potent direct thrombin inhibitor. Ximelagatran is a prodrug of thrombin inhibitor melagatran.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

116M4727V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pharmacogenetics of drug-induced liver injury.

Stefan Russmann et al.

Hepatology (Baltimore, Md.), 52(2), 748-761 (2010-07-08)

Recent progress in research on drug-induced liver injury (DILI) has been determined by key developments in two areas. First, new technologies allow the identification of genetic risk factors with improved sensitivity, specificity, and efficiency. Second, new mechanistic concepts of DILI

Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.

Erik Sjögren et al.

Pharmaceutical research, 27(4), 597-607 (2010-02-09)

The double prodrug, ximelagatran, is bioconverted, via the intermediates ethylmelagatran and N-hydroxymelagatran, to the direct thrombin inhibitor, melagatran. The primary aim of this study was to investigate the hepatic metabolism and disposition of ximelagatran and the intermediates in pig. A

Ximelagatran (Exanta): alternative to warfarin?

Vaughan C.

Proceedings (Baylor University. Medical Center), 18(1), 76-80 (2005)

View All Related Papers

Global Trade Item Number

SKU	GTIN
SML1768-5MG	04061832275291
SML1768-25MG	04061832275284